AHA Video: New Options for Atrial Fibrillation Patients

Dr. Gordon F. Tomaselli, chief of the Division of Cardiology at Johns Hopkins University School of Medicine, says that for the first time there are other options besides warfarin for treating patients at risk of thromboembolic complications of atrial fibrillation.

In this interview with Michel L. Zoler, he discusses the clinical and cost implications of dabigatran and the new rivaroxaban data.

Watch the interview conducted at the American Heart Association annual scientific sessions here.